Pfizer Inc. (PFE) EV/EBITDA Ratio: 12.66x
Is Pfizer Inc.’s EV/EBITDA ratio high or low?
Pfizer Inc.'s EV/EBITDA ratio of 12.66x is in line with its 5-year average of 13.74x, near the low end of its 5-year range (6.05x–43.67x).
As of Wednesday, June 17, 2026. 19.91% above its 12-month average of 10.56x.
PFE EV/EBITDA Ratio Chart
PFE Average EV/EBITDA Ratio Chart
PFE Current vs Average EV/EBITDA Ratio Chart
PFE EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
12.66x
EV/EBITDA RATIO AVG TTM
10.56x
EV/EBITDA RATIO AVG 3Y
11.83x
EV/EBITDA RATIO AVG 5Y
11.19x
EV/EBITDA RATIO AVG 10Y
11.92x
EV/EBITDA RATIO AVG 15Y
11.36x
EV/EBITDA RATIO AVG 20Y
10.64x
CURRENT VS TTM AVG
+19.91%
CURRENT VS 3Y AVG
+7.00%
CURRENT VS 5Y AVG
+13.15%
CURRENT VS 10Y AVG
+6.19%
CURRENT VS 15Y AVG
+11.41%
CURRENT VS 20Y AVG
+18.99%
PFE Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pfizer Inc. (PFE) | $148.41B | 12.66x | 10.56x | 11.83x | 11.19x |
| Intuitive Surgical, Inc. (ISRG)vs › | $145.70B | 34.27x | 46.88x | 54.26x | 52.27x |
| Abbott Laboratories (ABT)vs › | $157.84B | 16.55x | 18.56x | 19.27x | 18.55x |
| Gilead Sciences, Inc. (GILD)vs › | $158.06B | 12.42x | 14.07x | 17.97x | 15.91x |
| Danaher Corporation (DHR)vs › | $128.06B | 21.34x | 23.46x | 23.90x | 22.36x |
| CVS Health Corporation (CVS)vs › | $127.73B | 17.75x | 15.00x | 11.89x | 12.02x |
| Thermo Fisher Scientific Inc. (TMO)vs › | $175.64B | 19.37x | 19.79x | 20.46x | 20.32x |
| Stryker Corporation (SYK)vs › | $119.06B | 21.49x | 30.83x | 30.63x | 30.62x |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $115.02B | 20.90x | 22.81x | 82.27x | 54.94x |
| Bristol-Myers Squibb Company (BMY)vs › | $114.19B | 10.85x | 9.67x | 16.61x | 15.44x |
EV/EBITDA vs. its own history
At 12.7, EV/EBITDA is richer than usual, sitting higher than 71% of its 20-year history.
20-year low
4.5
median
10.2
20-year high
43.7
Pfizer Inc. EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for Pfizer Inc. (PFE)?
- The EV/EBITDA ratio for PFE stock is 12.66x.
- Is Pfizer Inc.'s EV/EBITDA ratio high or low?
- Pfizer Inc.'s EV/EBITDA ratio of 12.66x is in line with its 5-year average of 13.74x, near the low end of its 5-year range (6.05x–43.67x).
- What is the TTM average EV/EBITDA ratio for Pfizer Inc. (PFE)?
- The TTM average EV/EBITDA ratio for PFE stock is 10.56x.
- What is the 3Y average EV/EBITDA ratio for Pfizer Inc. (PFE)?
- The 3Y average EV/EBITDA ratio for PFE stock is 11.83x.
- What is the 5Y average EV/EBITDA ratio for Pfizer Inc. (PFE)?
- The 5Y average EV/EBITDA ratio for PFE stock is 11.19x.
- What is the 10Y average EV/EBITDA ratio for Pfizer Inc. (PFE)?
- The 10Y average EV/EBITDA ratio for PFE stock is 11.92x.
- What is the 15Y average EV/EBITDA ratio for Pfizer Inc. (PFE)?
- The 15Y average EV/EBITDA ratio for PFE stock is 11.36x.
- What is the 20Y average EV/EBITDA ratio for Pfizer Inc. (PFE)?
- The 20Y average EV/EBITDA ratio for PFE stock is 10.64x.
Pfizer Inc. EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-16 | 12.66x |
| 2026-06-15 | 12.64x |
| 2026-06-12 | 12.72x |
| 2026-06-11 | 12.70x |
| 2026-06-10 | 12.51x |
| 2026-06-09 | 12.54x |
| 2026-06-08 | 12.51x |
| 2026-06-05 | 12.66x |
| 2026-06-04 | 12.54x |
| 2026-06-03 | 12.42x |
| 2026-06-02 | 12.49x |
| 2026-06-01 | 12.52x |
| 2026-05-29 | 12.71x |
| 2026-05-28 | 12.69x |
| 2026-05-27 | 12.72x |
| 2026-05-26 | 12.59x |
| 2026-05-22 | 12.61x |
| 2026-05-21 | 12.63x |
| 2026-05-20 | 12.57x |
| 2026-05-19 | 12.53x |
| 2026-05-18 | 12.41x |
| 2026-05-15 | 12.41x |
| 2026-05-14 | 12.56x |
| 2026-05-13 | 12.63x |
| 2026-05-12 | 12.60x |
| 2026-05-11 | 12.58x |
| 2026-05-08 | 12.53x |
| 2026-05-07 | 12.81x |
| 2026-05-06 | 12.83x |
| 2026-05-05 | 12.80x |
| 2026-05-04 | 12.86x |
| 2026-05-01 | 12.87x |
| 2026-04-30 | 12.99x |
| 2026-04-29 | 12.85x |
| 2026-04-28 | 12.92x |
| 2026-04-27 | 13.03x |
| 2026-04-24 | 13.10x |
| 2026-04-23 | 12.98x |
| 2026-04-22 | 13.03x |
| 2026-04-21 | 13.20x |
| 2026-04-20 | 13.27x |
| 2026-04-17 | 13.29x |
| 2026-04-16 | 13.17x |
| 2026-04-15 | 13.16x |
| 2026-04-14 | 13.13x |
| 2026-04-13 | 13.21x |
| 2026-04-10 | 13.07x |
| 2026-04-09 | 13.17x |
| 2026-04-08 | 13.26x |
| 2026-04-07 | 13.13x |
| 2026-04-06 | 13.38x |
| 2026-04-02 | 13.54x |
| 2026-04-01 | 13.62x |
| 2026-03-31 | 13.46x |
| 2026-03-30 | 13.36x |
| 2026-03-27 | 13.11x |
| 2026-03-26 | 13.29x |
| 2026-03-25 | 13.19x |
| 2026-03-24 | 13.08x |
| 2026-03-23 | 13.02x |
| 2026-03-20 | 13.09x |
| 2026-03-19 | 13.24x |
| 2026-03-18 | 13.20x |
| 2026-03-17 | 13.25x |
| 2026-03-16 | 12.96x |
| 2026-03-13 | 12.95x |
| 2026-03-12 | 13.05x |
| 2026-03-11 | 13.20x |
| 2026-03-10 | 13.15x |
| 2026-03-09 | 13.03x |
| 2026-03-06 | 13.11x |
| 2026-03-05 | 12.96x |
| 2026-03-04 | 12.97x |
| 2026-03-03 | 12.95x |
| 2026-03-02 | 13.18x |
| 2026-02-27 | 13.32x |
| 2026-02-26 | 13.13x |
| 2026-02-25 | 10.16x |
| 2026-02-24 | 10.18x |
| 2026-02-23 | 10.16x |
| 2026-02-20 | 10.04x |
| 2026-02-19 | 10.10x |
| 2026-02-18 | 10.24x |
| 2026-02-17 | 10.24x |
| 2026-02-13 | 10.30x |
| 2026-02-12 | 10.27x |
| 2026-02-11 | 10.34x |
| 2026-02-10 | 10.30x |
| 2026-02-09 | 10.15x |
| 2026-02-06 | 10.20x |
| 2026-02-05 | 10.00x |
| 2026-02-04 | 10.08x |
| 2026-02-03 | 9.81x |
| 2026-02-02 | 10.05x |
| 2026-01-30 | 9.99x |
| 2026-01-29 | 9.90x |
| 2026-01-28 | 9.83x |
| 2026-01-27 | 10.00x |
| 2026-01-26 | 9.84x |
| 2026-01-23 | 9.77x |
| 2026-01-22 | 9.90x |
| 2026-01-21 | 9.84x |
| 2026-01-20 | 9.74x |
| 2026-01-16 | 9.77x |
| 2026-01-15 | 9.84x |
| 2026-01-14 | 9.76x |
| 2026-01-13 | 9.64x |
| 2026-01-12 | 9.67x |
| 2026-01-09 | 9.73x |
| 2026-01-08 | 9.68x |
| 2026-01-07 | 9.67x |
| 2026-01-06 | 9.72x |
| 2026-01-05 | 9.65x |
| 2026-01-02 | 9.65x |
| 2025-12-31 | 9.57x |
| 2025-12-30 | 9.60x |
| 2025-12-29 | 9.60x |
| 2025-12-26 | 9.62x |
| 2025-12-24 | 9.61x |
| 2025-12-23 | 9.57x |
| 2025-12-22 | 9.66x |
| 2025-12-19 | 9.65x |
| 2025-12-18 | 9.61x |
| 2025-12-17 | 9.61x |
| 2025-12-16 | 9.74x |
| 2025-12-15 | 9.99x |
| 2025-12-12 | 9.83x |
| 2025-12-11 | 9.82x |
| 2025-12-10 | 9.81x |
| 2025-12-09 | 9.69x |
| 2025-12-08 | 9.81x |
| 2025-12-05 | 9.88x |
| 2025-12-04 | 9.79x |
| 2025-12-03 | 9.75x |
| 2025-12-02 | 9.64x |
| 2025-12-01 | 9.67x |
| 2025-11-28 | 9.80x |
| 2025-11-26 | 9.79x |
| 2025-11-25 | 9.79x |
| 2025-11-24 | 9.66x |
| 2025-11-21 | 9.61x |
| 2025-11-20 | 9.44x |
| 2025-11-19 | 9.57x |
| 2025-11-18 | 9.72x |
| 2025-11-17 | 9.62x |
| 2025-11-14 | 9.62x |
| 2025-11-13 | 9.81x |
| 2025-11-12 | 9.83x |
| 2025-11-11 | 9.74x |
| 2025-11-10 | 9.43x |
| 2025-11-07 | 9.45x |
| 2025-11-06 | 9.56x |
| 2025-11-05 | 9.49x |
| 2025-11-04 | 9.41x |
| 2025-11-03 | 8.82x |
| 2025-10-31 | 8.82x |
| 2025-10-30 | 8.73x |
| 2025-10-29 | 8.73x |
| 2025-10-28 | 8.78x |
| 2025-10-27 | 8.85x |
| 2025-10-24 | 8.84x |
| 2025-10-23 | 8.82x |
| 2025-10-22 | 8.83x |
| 2025-10-21 | 8.87x |
| 2025-10-20 | 8.83x |
| 2025-10-17 | 8.78x |
| 2025-10-16 | 8.71x |
| 2025-10-15 | 8.75x |
| 2025-10-14 | 8.78x |
| 2025-10-13 | 8.84x |
| 2025-10-10 | 8.85x |
| 2025-10-09 | 8.97x |
| 2025-10-08 | 9.08x |
| 2025-10-07 | 9.22x |
| 2025-10-06 | 9.26x |
| 2025-10-03 | 9.50x |
| 2025-10-02 | 9.43x |
| 2025-10-01 | 9.46x |
| 2025-09-30 | 9.03x |
| 2025-09-29 | 8.62x |
| 2025-09-26 | 8.59x |
| 2025-09-25 | 8.55x |
| 2025-09-24 | 8.68x |
| 2025-09-23 | 8.69x |
| 2025-09-22 | 8.66x |
| 2025-09-19 | 8.66x |
| 2025-09-18 | 8.69x |
| 2025-09-17 | 8.67x |
| 2025-09-16 | 8.63x |
| 2025-09-15 | 8.65x |
| 2025-09-12 | 8.62x |
| 2025-09-11 | 8.87x |
| 2025-09-10 | 8.80x |
| 2025-09-09 | 8.83x |
| 2025-09-08 | 8.79x |
| 2025-09-05 | 8.87x |
| 2025-09-04 | 8.79x |
| 2025-09-03 | 8.85x |
| 2025-09-02 | 8.90x |
| 2025-08-29 | 8.84x |
| 2025-08-28 | 8.80x |
| 2025-08-27 | 8.92x |
| 2025-08-26 | 8.88x |
| 2025-08-25 | 8.94x |
| 2025-08-22 | 9.13x |
| 2025-08-21 | 9.09x |
| 2025-08-20 | 9.00x |
| 2025-08-19 | 8.99x |
| 2025-08-18 | 8.92x |
| 2025-08-15 | 8.94x |
| 2025-08-14 | 8.93x |
| 2025-08-13 | 8.94x |
| 2025-08-12 | 8.82x |
| 2025-08-11 | 8.80x |
| 2025-08-08 | 8.80x |
| 2025-08-07 | 8.71x |
| 2025-08-06 | 8.64x |
| 2025-08-05 | 8.84x |
| 2025-08-04 | 9.78x |
| 2025-08-01 | 9.77x |
| 2025-07-31 | 9.71x |
| 2025-07-30 | 9.86x |
| 2025-07-29 | 10.00x |
| 2025-07-28 | 10.01x |
| 2025-07-25 | 10.14x |
| 2025-07-24 | 10.30x |
| 2025-07-23 | 10.31x |
| 2025-07-22 | 10.24x |
| 2025-07-21 | 9.99x |
| 2025-07-18 | 10.05x |
| 2025-07-17 | 10.08x |
| 2025-07-16 | 10.09x |
| 2025-07-15 | 10.09x |
| 2025-07-14 | 10.30x |
| 2025-07-11 | 10.39x |
| 2025-07-10 | 10.43x |
| 2025-07-09 | 10.36x |
| 2025-07-08 | 10.38x |
| 2025-07-07 | 10.27x |
| 2025-07-03 | 10.31x |
| 2025-07-02 | 10.30x |
| 2025-07-01 | 10.22x |
| 2025-06-30 | 9.98x |
| 2025-06-27 | 9.97x |
| 2025-06-26 | 9.98x |
| 2025-06-25 | 9.99x |
| 2025-06-24 | 10.01x |
| 2025-06-23 | 9.92x |
| 2025-06-20 | 9.91x |
| 2025-06-18 | 9.88x |
| 2025-06-17 | 9.92x |
| 2025-06-16 | 10.03x |
| 2025-06-13 | 10.07x |
| 2025-06-12 | 10.16x |
| 2025-06-11 | 10.05x |
| 2025-06-10 | 10.00x |
| 2025-06-09 | 9.91x |
| 2025-06-06 | 9.73x |
| 2025-06-05 | 9.66x |
| 2025-06-04 | 9.74x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla